Objective. Interstitial lung disease (ILD) is a serious complication of SSc. We aimed to identify markers associated with SSc-related ILD.
Introduction
SSc is an autoimmune connective tissue disorder characterized by microvascular injury, skin fibrosis and distinctive visceral changes. SSc is a clinically heterogeneous disease, ranging from a mild form with less extensive involvement of the viscera to a more severe type with widespread visceral changes significantly affecting morbidity and mortality [14] . Interstitial lung disease (ILD), one of the most serious complications of SSc, develops in >50% of patients with SSc [5, 6] . In contrast to the recent improvements in the survival of patients with SSc complicated by renal crisis, the frequency of deaths due to ILD among SSc patients has increased significantly over the last 30 years, from 6 to 33% of SSc-related deaths [7] . Other studies have concurred that the presence of ILD is associated with a poorer prognosis in patients with SSc [810] . Although modest clinical efficacy of cyclophosphamide was reported in two high-quality randomized controlled trials [11, 12] , and potentially effective treatments, such as mycophenolate mofetil, imatinib mesylate or haematopoietic stem cell transplantation (HSCT), remain to be evaluated [13, 14] , the available treatments targeting SSc-related ILD are still limited. Therefore the search for novel biomarkers or genetic predispositions specific for SSc-related ILD is critical to provide new insights into the disease process, potentially leading in the longer term to a better prognosis for this severe visceral complication. Genetic backgrounds, up-regulated cytokines/growth factors and signal molecules such as HLA, PTPN22, CTGF, TGF-and PDGF have been implicated in the pathophysiology of SSc [1517] . However, until recently, few studies have focused on specific biomarkers in SSc-related ILD.
In the present study we aimed to identify up-regulated molecule(s) in patients with SSc-related ILD based on an unbiased microarray analysis using pooled RNA samples. The analysis of four pools of RNA derived from peripheral blood mononuclear cells (PBMCs) identified HLA-DRB5 as a candidate up-regulated gene in patients with ILD. We then confirmed its expression in individual patients and also genotyped the HLA-DRB5 gene in two cohorts. Detailed genotyping led us to identify the specific HLA-DRB5 allele *01:05 as a novel risk factor for SSc-related ILD.
Patients and methods
This study was approved by the ethical committees of the Hokkaido University Graduate School of Medicine and the Tokyo Women's Medical University. Informed patient consent was obtained for this study.
Global gene expression analysis using DNA microarray
We first evaluated global gene expression profiles in pooled RNA from the PBMCs of patients with SSc. Four sets of RNA pools were prepared from PBMCs from 14 SSc patients seen at the Hokkaido University Hospital. The first pool was prepared from four patients with ILD [three females, median age 46 (3058) years, median disease duration 84 (70119) months] who received only conventional therapies [prostaglandin and/or the following immunosuppressive agents: prednisolone (n = 1), ciclosporin (n = 1), tacrolimus (n = 1) and CYC (n = 1)]. The second pool was derived from four patients without ILD [three females, median age 60 (4064) years, median disease duration 102 (60234) months] who received conventional therapies [prostaglandin and/or immunosuppressive agents: ciclosporin (n = 1)]. The third pool included four patients with ILD [three females, median age 39 (2261) years, median disease duration 93 (66103) months] who received HSCT. The last array comprised two patients without ILD [one female, median age 49 (3365) years, median disease duration 93 (54132) months] who received HSCT. The mixed RNA samples in each pool were subjected to a single DNA microarray (Affymetrix GeneChip Human Gene 1.0 ST Array, Affymetrix, Santa Clara, CA, USA). Data were analysed using GeneSpring GX version 10.0 (Agilent Technologies, Inc., Santa Clara, CA, USA). The fluorescence intensity results were defined as RAW normalized according to the Robust Multi-array Average algorithm. To normalize the treatment background of the patients, the first comparison performed was with the conventional therapy group, and the second was with the HSCT group. Up-regulated genes were defined as those for which the gene expression in the first or the third pool increased more than 3-fold relative to that in the second or the fourth pool, respectively.
Quantitative real-time PCR 5 were treated by HSCT and 20 were on immunosuppressive agents [prednisolone (n = 10), cyclosporin (n = 6), tacrolimus (n = 4), CYC (n = 2) and D-Pen (n = 3)]. Among the patients without ILD, 3 were treated by HSCT, and 15 were on prostaglandin and/or immunosuppressive agents [prednisolone (n = 6), ciclosporin (n = 2) and D-Pen (n = 5)]. As control groups, PBMCs were also collected from 42 patients with other autoimmune diseases [RA (n = 20 and DM/PM (n = 22)] and from 10 healthy controls. The expression levels of HLA-DRB5 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in each individual were evaluated by real-time quantitative PCR using TaqMan Gene Expression assays (HLA-DRB5 assay ID: Hs03046116_m1, GAPDH assay ID: Hs9999905_m1), TaqMan Universal PCR Master Mix and the ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA). Relative quantification was performed using the comparable cycle threshold (CT) method in which ÁCT is defined as the level of the HLA-DRB5 transcript in the RNA sample relative to that of the GAPDH transcript, as previously reported [18] .
Genomic DNA extraction and genotyping of HLA-DRB5 and HLA-DRB1
The first cohort comprised 70 Japanese patients with SSc who visited the Hokkaido University Hospital and fulfilled the 1980 criteria of the ACR [19] and 147 disease-free Japanese volunteers residing in the Hokkaido area as healthy controls. Patients with SSc were classified as either having ILD (n = 41) or not having ILD (n = 29) based on HRCT, as described in the next subsection. Of the 41 patients with ILD, 6 were treated with HSCT using autologous peripheral blood stem cells, and the other 35 patients received conventional therapy. HSCT was performed as previously described [20] . Of the six patients who received HSCT, three also received ciclosporin for recurrent or progressive scleroderma. Conventional therapy included prostaglandin and immunosuppressive agents [prednisolone (n = 16), ciclosporin (n = 5), tacrolimus (n = 7), CYC (n = 2) and/or D-Pen (n = 5)]. Of the 29 patients without ILD, 4 were treated with HSCT and the other 25 with conventional therapy. Patients with other autoimmune diseases comprised 20 with RA and 29 with DM or PM. RA patients fulfilled the ACR criteria [21] , and DM/PM patients fulfilled the Bohan and Peter criteria [22, 23] . The second cohort comprised 83 disease-free Japanese volunteers residing in the Tokyo area and 79 Japanese patients with SSc observed at the Tokyo Women's Medical University Hospital. These patients with SSc were classified as having ILD (n = 40) or as not having ILD (n = 39) ( Table 1) .
Genomic DNA samples were extracted using DNA Quick II (DS Pharma Biomedical Co. Ltd, Osaka, Japan), according to the manufacturer's instructions. HLA-DRB5 genotyping was performed by PCR with sequencespecific primers (PCR-SSP) using Olerup SSP HLA-DRB5 (Olerup SSP AB, Saltsjö baden, Sweden). All of the 19 known alleles of HLA-DRB5 are theoretically identifiable using this PCR-SSP method [24, 25] . The HLA-DRB1 alleles were determined using the PCR-SSOP Luminex method with LABType SSO (One Lambda Inc., Canoga Park, CA, USA), a reverse SSO DNA typing system, according to the manufacturer's instructions.
Evaluation of pulmonary and other organ involvement
The presence or absence of ILD was evaluated using HRCT in all of our patients with SSc. The diagnosis of ILD was made when one or more of the following features were evident: isolated ground-glass opacities, honeycombing, ground-glass attenuation and/or traction bronchiectasis. After the diagnosis of ILD was made, the HRCT findings were classified into the following: non-specific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), or organizing pneumonia (OP). Pulmonary hypertension (PH) was screened for by echocardiography and confirmed by right-heart catheterization [26] . Other organ involvement was defined as follows: renal (renal crisis in patients with SSc and nephritis in other autoimmune diseases), cardiac (arrhythmia), joint (arthritis) and muscle (continuous increase in serum creatinine kinase and/or serum aldolase levels, electromyogram and/or muscle biopsy).
Autoantibodies ANA was detected with IIF. A titre of 1:80 or more was considered to be positive. Anti-topo-I antibody (anti-Topo-I), ACA, anti-U1-RNP antibody and anti-SS-A antibody levels were examined using enzyme-linked immunoassays (MESACUP, Medical & Biological Laboratories Co., Ltd, Japan), RF levels were evaluated by the latex turbidimetric assay (N-assay TIA RF Nittobo, Nittobo 
Results

Evaluation of global gene expression
In the patients who received HSCT, two genes were up-regulated in patients with ILD relative to those without ILD. In the conventional treatment group, 17 genes were up-regulated in patients with ILD compared with those without ILD. Of these genes, HLA-DRB5 was the only commonly up-regulated gene in both comparisons (Table 2) .
Quantitative real-time PCR
HLA-DRB5 gene expression levels were higher in the PBMCs from SSc patients with ILD than in those patients without ILD (Fig. 1) . HLA-DRB5 expression levels were related neither to disease duration nor to the presence or absence of immunotherapy (data not shown). In the relatively small numbers of patients with other autoimmune disease, there were apparently no differences in the levels of HLA-DRB5 gene expression between patients with ILD and those without ILD or healthy controls.
HLA-DRB5 genotyping (the first cohort)
The prevalence of HLA-DRB5 gene carriers among SSc patients was not significantly different from that in healthy controls. The prevalence of HLA-DRB5 gene carriers in patients with RA or DM/PM was also not different from that in healthy controls. However, the prevalence of HLA-DRB5 gene carriers was higher in SSc patients with ILD than in those without ILD or in healthy controls. In contrast, HLA-DRB5 was not associated with ILD in patients with RA or DM/PM, although the sample size for our autoimmune control group was relatively small (Table 3) . In patients with SSc, HLA-DRB5 was not associated with other clinical complications such as PH, renal crisis or digital ulcer in patients with SSc or in the presence or absence of the evaluated autoantibodies (data not shown).
Genotyping of the HLA-DRB5 gene revealed 4 of the known 19 alleles in the SSc patients and healthy controls: *01:01, *01:02, *01:05 and *02:02. Among the different HLA-DRB5 alleles, the HLA-DRB5*01:05 allele was significantly more frequent in SSc patients than in the controls. More specifically, DRB5*01:05 was significantly more frequent in SSc patients with ILD, but not in SSc patients without ILD, compared with healthy controls (Table 4 ). In addition, the DRB5*01:05 allele was more frequent in SSc patients with ILD than in those without ILD.
In the univariate analysis, the presence of the DRB5*01:05 allele was associated with PH. However, no other clinical features, including age, gender, disease duration, renal crisis and all of the tested autoantibodies, were related to the presence of the DRB5*01:05 allele ( Table 5 ). The DRB5*01:05 allele was not associated with ILD in patients with RA or PM/DM (data not shown).
HLA-DRB1 genotyping (the first cohort)
The frequencies of the HLA-DRB1 alleles in the 70 SSc patients from the first cohort are shown in supplementary data Table 1 , available as supplementary data at Rheumatology Online. A total of 20 HLA-DRB1 alleles were identified. Of these alleles, the HLA-DRB1*15:02 allele was more frequent in SSc patients with anti-Topo-I (50.0%) than in those patients without anti-Topo-I (20.8%, P = 0.013) but was not significantly increased in 
Multivariate analysis (the first cohort)
In a multivariate analysis composed of clinical and demographic parameters after the inclusion of the HLA alleles, we identified HLA-DRB5*01:05 and anti-Topo-I as independent risk factors for ILD (P = 0.024 and 0.011, respectively). Other parameters, such as HLA-DRB1*15:02 or other DRB5 alleles, were not significantly associated with ILD (supplementary data Table 2 , available as supplementary data at Rheumatology Online).
HLA-DRB5 genotyping (the second cohort)
The prevalence of HLA-DRB5 gene carriers in SSc patients was not significantly different from that in healthy controls. The prevalence of HLA-DRB5 gene carriers was higher in SSc patients with ILD than in those without ILD or in healthy controls (Table 2) . Neither clinical complications, such as PH, renal crisis or digital ulcer, nor measured autoantibody levels were associated with the HLA-DRB5 allele (data not shown).
No association was found between SSc and the DRB5*01:05 allele in the second cohort. The HLA-DRB5*01:05 allele was significantly more frequent in patients with ILD than in healthy controls (Table 4) . Thus the associations between SSc-related ILD and the DRB5*01:05 allele were confirmed in the second cohort.
On univariate analysis, no clinical factors except ILD correlated with the presence of the DRB5*01:05 allele (Table 5 ).
Discussion
The HLA-DRB5 locus and its alleles have rarely been brought to researchers' attention in terms of disease susceptibility. Taking advantage of unbiased mRNA expression profiling using pooled PBMC samples from SSc patients with or without ILD, we focused on HLA-DRB5 and confirmed the high expression of this gene in individual patients with SSc-related ILD compared with those without ILD. Furthermore, we identified the HLA-DRB5*01:05 allele as a novel risk factor for ILD in SSc using a genotyping approach. Due to the limitations of our cohort in terms of relatively small size and uniform ethnicity, our results clearly need to be confirmed in a larger cohort or in other ethnicities. As many of the RNA samples were obtained from patients currently under treatment, prospective observation would also be desirable to determine whether HLA-DRB5 expression in PBMCs or the HLA-DRB5*01:05 allele has predictive value for the development of ILD in patients with early-stage SSc. However, because HLA-DRB5 expression is genetically regulated and is unaffected by disease duration or immunotherapy, it is highly unlikely that there is any significant discrepancy between HLA-DRB5 expression levels and genotype.
The first genome-wide association study concerning SSc in a sample of European ancestry confirmed the role of HLA gene regions as SSc genetic risk factors with the strongest association [27] . Previously, HLA studies in SSc have suggested that MHC genes exert their influence through the presentation of a specific self-antigen [28] . In the Japanese population, the frequencies of DRB1*15:02, DQB1*06:01 and DPB1*09:01 have been reported to be significantly increased in anti-Topo-I-positive patients [29] . In terms of pulmonary complications, an association between DR3/DR52a and pulmonary fibrosis has been documented in Caucasian patients with SSc [30] . However, HLA-DR3 is quite rare in the Japanese population, and, in fact, none of the investigated individuals in our first cohort had a DRB1 allele corresponding to this serotype. The correlation between the HLA-DRB1*15:02 allele and anti-Topo-I antibodies was confirmed in our study, as well as the absence of a significant correlation between this allele and SSc or SSc-related ILD. HLA-DRB5 belongs to the HLA class II beta chain paralogues. Currently 19 alleles have been identified for the HLA-DRB5 gene, and several studies have reported the frequencies of HLA-DRB5 alleles and the DRB5-DRB1-DQB1 haplotype in healthy and diseased populations [3133] . However, no report has referred to the frequencies of the HLA-DRB5*01:05 allele or the DRB5*01:05-DRB1 haplotype. Although the frequency of the HLA-DRB5*01:05 allele in the healthy Japanese population has not yet been reported, we determined, using our own healthy cohorts, that HLA-DRB5*01:05 is associated with SSc-related ILD, with odds ratios ranging from 8.07 to 17.39 (Table 4) . Our multivariate analysis also identified HLA-DRB5*01:02 and anti-Topo-I as risk factors for SSc-related ILD (supplementary data Table 2 , available as supplementary data at Rheumatology Online). Although the HLA-DRB5 locus is almost exclusively carried by HLA-DRB1*15 and HLA-DRB1*16 haplotypes, neither of these alleles were related to ILD (supplementary data Table 1 , available as supplementary data at Rheumatology Online). The lack of correlation between HLA-DRB5*01:05 and any of the investigated autoantibodies suggests the existence of unknown or unstudied autoantibodies strongly related to ILD in SSc. Further investigation is necessary to identify the lung-related self antigen(s) recognized by HLA haplotypes, including this DRB5 allele. Of note, the HLA-DRB5*01:05 allele is not more frequent in SSc patients without ILD relative to healthy controls. Although the possibility remains that another molecule in linkage disequilibrium with this HLA-DRB5 allele is responsible for the development of ILD in SSc patients, the increase in the HLA-DRB5 transcripts in SSc-ILD patients reveals that HLA-DRB5 itself is a risk for this visceral complication.
In conclusion, we determined in two Japanese cohorts that HLA-DRB5 gene carriers were more frequent in SSc patients with ILD than in those without ILD or in healthy controls. In particular, the HLA-DRB5*01:05 allele was more frequent in SSc patients with ILD than in those without, with stronger statistical significance. HLA-DRB5*01:05 is a novel candidate for a risk factor for developing ILD in patients with SSc.
Rheumatology key messages
. HLA-DRB5 transcripts were up-regulated in peripheral blood of SSc patients with ILD. . HLA-DRB5 carriers were more prevalent in SSc patients with ILD than in those without. . The HLA-DRB5*01:05 allele is a risk for the development of ILD in patients with SSc. *P = 0.036, **P = 0.030, ***P < 0.001. The chi-squared test or Fisher's exact test was used. OR: odds ratio; SRC: scleroderma renal crisis; aTopo-I: anti-topoisomerase-I antibody; aU1-RNP: anti-U1-RNP antibody; aSS-A/Ro: anti-SS-A antibody.
